Axonal Regulation of Myelination by Neuregulin 1 Klaus-Armin Nave1,2 and James L Salzer3

Total Page:16

File Type:pdf, Size:1020Kb

Axonal Regulation of Myelination by Neuregulin 1 Klaus-Armin Nave1,2 and James L Salzer3 Axonal regulation of myelination by neuregulin 1 Klaus-Armin Nave1,2 and James L Salzer3 Neuregulins comprise a family of epidermal growth factor-like In this review, we describe recent progress in elucidating ligands that interact with ErbB receptor tyrosine kinases to the mechanisms by which motor and sensory axons in the control many aspects of neural development. One of the most peripheral nervous system (PNS) regulate the develop- dramatic effects of neuregulin-1 is on glial cell differentiation. ment and differentiation of Schwann cells, most strikingly The membrane-bound neuregulin-1 type III isoform is an axonal during myelination. Unexpectedly, a single growth factor, ligand for glial ErbB receptors that regulates the early Schwann neuregulin-1 (NRG1), has emerged as the pivotal signal cell lineage, including the generation of precursors. Recent that controls Schwann cells at every stage of the lineage. studies have shown that the amount of neuregulin-1 type III expressed on axons also dictates the glial phenotype, with a Neuregulin-1 and ErbB receptors threshold level triggering Schwann cell myelination. The Neuregulin-1 (NRG1) family comprises more than Remarkably, neuregulin-1 type III also regulates Schwann cell 15 membrane-associated and secreted proteins [4,5]. membrane growth to adjust myelin sheath thickness to match These are derived from one of the largest mammalian axon caliber precisely. Whether this signaling system operates genes (on human chromosome 8p22 and mouse chromo- in central nervous system myelination remains an open some 8A3) and are generated by use of multiple tran- question of major importance for human demyelinating scription sites and by extensive alternative RNA splicing diseases. [6]. All NRG1 isoforms share an epidermal growth factor Addresses (EGF)-like signaling domain that is necessary and suffi- 1 Max Planck Institute of Experimental Medicine, D-37075 Goettingen, cient for activation of their receptors. NRG1 isoforms are Germany subdivided into several subtypes on the basis of their 2 Hertie Institute of Multiple Sclerosis Research, Goettingen, Germany 3 Departments of Cell Biology and Neurology, and the Molecular distinct amino-termini [4,7]. NRG1 type I (also known as Neurobiology Program, Skirball Institute of Biomolecular Medicine, New heregulin, neu differentiation factor, or acetylcholine York University School of Medicine, New York, NY 10016, USA receptor-inducing activity [ARIA]) and NRG1 type II (also known as glial growth factor [GGF]) have N-term- Corresponding author: Nave, Klaus-Armin ([email protected]) inal immunoglobulin-like domains. Transmembrane forms of NRG1 undergo proteolytic cleavage by metal- Current Opinion in Neurobiology 2006, 16:492–500 loproteinases (MP), including TACE (tumor-necrosis factor-a-converting enzyme) [8]. As a consequence, This review comes from a themed issue on NRG1 type I and II are shed from the neuronal cell Neuronal and glial cell biology Edited by Kelsey C Martin and Elior Peles surface and function as paracrine signaling molecules (schematically depicted in Figure 1). NRG1 type III is Available online 7th September 2006 defined by its cysteine-rich domain (CRD), which func- 0959-4388/$ – see front matter tions as a second transmembrane domain. Consequently, # 2006 Elsevier Ltd. All rights reserved. NRG1 type III remains tethered to the cell surface after cleavage and functions as a juxtacrine signal [9]. In DOI 10.1016/j.conb.2006.08.008 addition, exons encoding shorter amino termini of NRG1 have been identified by sequence analysis (referred to as types IV–VI), but these isofoms have Introduction not been further characterized [10]. NRG1 expression Reciprocal interactions between neurons and glia are is not specific to the nervous system, it also has a major crucial for the organization and function of the nervous role in cardiac and mammary tissue development system, from neurogenesis in embryonic development to (reviewed in [11]). Indeed, mice lacking NRG1, or its synaptic plasticity in the adult brain. Glial cells that receptors (ErbB2, ErbB3 and ErbB4), are embryonic synthesize myelin are essential for normal motor and lethal because NRG1–ErbB signaling is essential for cognitive functions, with the fine tuning of myelination cardiac development. contributing to the millisecond precision of the nervous system [1]. Furthermore, myelin-forming glial cells are Within the nervous system, NRG1 types I and III are the also required for the long-term integrity of axons, inde- most abundant forms and have been detected in many pendently of myelin itself [2,3]. Axons, in turn, crucially projection neurons, most notably in spinal motor neurons regulate the behavior of myelinating glia: that is, Schwann and dorsal root ganglia (DRG) neurons, but also in glia cells and oligodendrocytes. However, the molecular [4,12]. In addition to the axon–glia signaling detailed mechanisms by which neurons and glial cells commu- below, the proposed functions of NRG1 include the devel- nicate remain poorly understood. opment of motor endplates, migration of interneurons, and Current Opinion in Neurobiology 2006, 16:492–500 www.sciencedirect.com Axonal regulation of myelination by neuregulin 1 Nave and Salzer 493 Figure 1 NRG1 isoforms: membrane disposition and signalling. (a) Types I and II are synthesized as single pass transmembrane proteins; Type III has two transmembrane domains. (b) With metalloproteinase (MP) cleavage, types I and II are shed as paracrine signals, type III remains tethered through its cysteine rich domain (CRD) and is a juxtacrine signal; this cleavage is enhanced by neurotrophins released by Schwann cells. The cytoplasmic domain undergoes further cleavage stimulated by binding of ErbB receptors to NRG1, followed by translocation to the nucleus. See [4]for additional details. synaptogenesis and synaptic plasticity in the CNS [5]. adaptor molecules and activation of downstream signaling Many NRG1-expressing neurons also express transcripts pathways (see below). Whereas Schwann cells principally for NRG2 and NRG3, two structurally related growth express ErbB2 and ErbB3, cells in the oligodendrocyte factors with EGF-like signaling domains, the function of lineage express all three ErbB receptors, in a developmen- which in the nervous system remains largely unknown tally regulated manner, in addition to the EGFR (ErbB1), [12,13]. indicating significant complexity of potential ErbB recep- tor heterodimers and downstream signaling events in these ErbB receptors cells [16,17]. NRG1 isoforms mediate their effects by binding to ErbB receptors, members of the EGF receptor superfamily [14]. NRG1 ‘back signaling’ NRG1 binds to either ErbB3, which lacks an active kinase Intriguingly, NRG1 might also signal bidirectionally. Bind- domain, or ErbB4, which has such a kinase domain; each ing of recombinantly produced ‘soluble’ ErbB receptors to receptor, in turn, can heterodimerize with ErbB2, which membrane-bound NRG1 type III of transfected neurons cannot bind NRG1 directly but also has an active kinase results in proteolytic cleavage of NRG1, releasing its domain. ErbB receptors dimerize not by virtue of a brid- cytoplasmic C-terminal domain (CTD) from the mem- ging effect of NRG1, but following a ligand-activated brane [18]. Remarkably, the CTD then rapidly translocates conformational change in the ectodomain of ErbB3 or into the cell nucleus of the cultured neurons where it ErbB4 [15]. Crystallographic data indicate that ErbB2 activates transcription and enhances survival. Whether constitutively exposes a dimerization loop required to NRG1 ‘backsignaling’ occurs in vivo, particularly when form heterodimers with ligand-activated ErbB3 or ErbB4 NRG1 expressed on the axon is engaged by ErbB receptors receptors. Because the ability of ErbB2 to form homodi- of myelinating glia, remains to be established. It will also be mers is poor, and ErbB4 is minimally expressed by important to determine whether loss of the anti-apoptotic Schwann cells, ErbB2–ErbB3 is the relevant NRG1 effect of the CTD is normally responsible for the degen- Schwann cell receptor. NRG1 binding induces ErbB2– eration of dorsal root ganglion (DRG) and motor neurons ErbB3 heterodimer formation, which leads to receptor that is observed in NRG1 null mutant mice. Alternatively, cross-phosphorylation, recruitment of SH3-containing conventional NRG1 (forward) signaling could elicit www.sciencedirect.com Current Opinion in Neurobiology 2006, 16:492–500 494 Neuronal and glial cell biology reciprocal trophic support of ensheathed axons, such as indicate that final matching of SCPs to axons is mediated through NRG1-stimulated release of neurotrophins by glia through competition for a NRG1-mediated survival sig- [19]. Finally, the cytoplasmic tail of NRG1 has been nal [24–26]. NRG1 type III is the key isoform required reported to interact directly with LIM kinase, a regulator for SCP survival and migration during early embryogen- of the actin cytoskeleton [20]; the biological significance of esis [26]. this interaction is not yet established. Threshold levels of NRG1 type III are an instructive The role of NRG1 in Schwann cell myelination signal for myelination NRG1 has a crucial role at essentially every develop- Once generated, SCPs differentiate into mature Schwann mental stage of Schwann cells, as first indicated by both cells that either ensheath multiple small, unmyelinated culture studies and analysis of knockout mice [21,22]. axons, forming a Remak bundle, or sort larger axons into a These
Recommended publications
  • Signalling Between Microvascular Endothelium and Cardiomyocytes Through Neuregulin Downloaded From
    Cardiovascular Research (2014) 102, 194–204 SPOTLIGHT REVIEW doi:10.1093/cvr/cvu021 Signalling between microvascular endothelium and cardiomyocytes through neuregulin Downloaded from Emily M. Parodi and Bernhard Kuhn* Harvard Medical School, Boston Children’s Hospital, 300 Longwood Avenue, Enders Building, Room 1212, Brookline, MA 02115, USA Received 21 October 2013; revised 23 December 2013; accepted 10 January 2014; online publish-ahead-of-print 29 January 2014 http://cardiovascres.oxfordjournals.org/ Heterocellular communication in the heart is an important mechanism for matching circulatory demands with cardiac structure and function, and neuregulins (Nrgs) play an important role in transducing this signal between the hearts’ vasculature and musculature. Here, we review the current knowledge regarding Nrgs, explaining their roles in transducing signals between the heart’s microvasculature and cardiomyocytes. We highlight intriguing areas being investigated for developing new, Nrg-mediated strategies to heal the heart in acquired and congenital heart diseases, and note avenues for future research. ----------------------------------------------------------------------------------------------------------------------------------------------------------- Keywords Neuregulin Heart Heterocellular communication ErbB -----------------------------------------------------------------------------------------------------------------------------------------------------------† † † This article is part of the Spotlight Issue on: Heterocellular signalling
    [Show full text]
  • Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung
    ORIGINAL ARTICLE Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues Kuniko Sunami, MD,a,g Koh Furuta, MD, PhD,b Koji Tsuta, MD, PhD,c Shinji Sasada, MD, PhD,d Takehiro Izumo, MD, PhD,d Takashi Nakaoku, MD,a Yoko Shimada, MFSc,a Motonobu Saito, MD, PhD,a Hiroshi Nokihara, MD, PhD,e Shun-ichi Watanabe, MD, PhD,f Yuichiro Ohe, MD, PhD,e,g Takashi Kohno, PhDa,* aDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan bDivision of Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan cDivision of Pathology, National Cancer Center Research Institute, Tokyo, Japan dDepartment of Endoscopy, Respiratory Endoscopy Division, National Cancer Center Research Institute, Tokyo, Japan eDepartment of Thoracic Oncology, National Cancer Center Research Institute, Tokyo, Japan fDepartment of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan gCourse of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan Received 31 July 2015; revised 23 September 2015; accepted 13 October 2015 ABSTRACT detected oncogenic fusions in bronchial lavage fluid and transbronchial biopsy samples. Introduction: Fusions of the anaplastic lymphoma receptor tyrosine kinase gene (ALK), ret proto-oncogene (RET), ROS Conclusions: The MC assay allows multiplex detection of proto-oncogene 1, receptor tyrosine kinase gene (ROS1), B- oncogenic fusion and exon-skipped transcripts in tumor Raf proto-oncogene, serine/threonine kinase gene (BRAF), samples, including in formalin-fixed paraffin-embedded and neuregulin 1 gene (NRG1) and intronic MMNG HOS samples obtained in the clinic. Transforming gene (MET) mutations are druggable onco- Ó 2015 International Association for the Study of Lung gene alterations in lung adenocarcinoma that cause Cancer.
    [Show full text]
  • RET Controls Sympathetic Innervation
    Development 128, 3963-3974 (2001) 3963 Printed in Great Britain © The Company of Biologists Limited 2001 DEV8811 RET signaling is essential for migration, axonal growth and axon guidance of developing sympathetic neurons Hideki Enomoto1, Peter A. Crawford1, Alexander Gorodinsky1, Robert O. Heuckeroth2,3, Eugene M. Johnson, Jr3 and Jeffrey Milbrandt1,* 1Departments of Pathology and Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Box 8118, St Louis, MO 63110, USA 2Department of Pediatrics, Washington University School of Medicine, 660 South Euclid Avenue, Box 8116, St Louis, MO 63110, USA 3Department of Molecular Biology and Pharmacology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8113, St Louis, MO 63110, USA *Author for correspondence (e-mail: [email protected]) Accepted 26 July 2001 SUMMARY Sympathetic axons use blood vessels as an intermediate trunks and accelerated cell death of sympathetic neurons path to reach their final target tissues. The initial contact later in development. Artemin is expressed in blood vessels between differentiating sympathetic neurons and blood during periods of early sympathetic differentiation, and vessels occurs following the primary sympathetic chain can promote and attract axonal growth of the sympathetic formation, where precursors of sympathetic neurons ganglion in vitro. This analysis identifies RET and artemin migrate and project axons along or toward blood vessels. as central regulators of early sympathetic innervation. We demonstrate
    [Show full text]
  • Promoting Myelin Repair and Return of Function in Multiple Sclerosis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector FEBS Letters 585 (2011) 3813–3820 journal homepage: www.FEBSLetters.org Review Promoting myelin repair and return of function in multiple sclerosis Jingya Zhang a,b,c, Elisabeth G. Kramer a,b,c, Linnea Asp a,b,c, Dipankar J. Dutta a,b,c, Kristina Navrazhina a,b,c, Trinh Pham a,b,c, John N. Mariani a,b,c, Azeb Tadesse Argaw a,b,c, Carmen V. Melendez-Vasquez d, ⇑ Gareth R. John a,b,c, a Corinne Goldsmith Dickinson Center for MS, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029, USA b Department of Neurology, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029, USA c Friedman Brain Institute, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029, USA d Department of Biological Sciences, Hunter College, 695 Park Avenue, New York, NY 10065, USA article info abstract Article history: Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS. Conduction block in Received 7 July 2011 demyelinated axons underlies early neurological symptoms, but axonal transection and neuronal Revised 8 August 2011 loss are believed to be responsible for more permanent chronic deficits. Several therapies are Accepted 9 August 2011 approved for treatment of relapsing-remitting MS, all of which are immunoregulatory and clinically Available online 18 August 2011 proven to reduce the rate of lesion formation and exacerbation. However, existing approaches are Edited by Richard Williams, Alexander only partially effective in preventing the onset of disability in MS patients, and novel treatments Flügel and Wilhelm Just to protect myelin-producing oligodendrocytes and enhance myelin repair may improve long-term outcomes.
    [Show full text]
  • Biomarker Testing in Non- Small Cell Lung Cancer (NSCLC)
    The biopharma business of Merck KGaA, Darmstadt, Germany operates as EMD Serono in the U.S. and Canada. Biomarker testing in non- small cell lung cancer (NSCLC) Copyright © 2020 EMD Serono, Inc. All rights reserved. US/TEP/1119/0018(1) Lung cancer in the US: Incidence, mortality, and survival Lung cancer is the second most common cancer diagnosed annually and the leading cause of mortality in the US.2 228,820 20.5% 57% Estimated newly 5-year Advanced or 1 survival rate1 metastatic at diagnosed cases in 2020 diagnosis1 5.8% 5-year relative 80-85% 2 135,720 survival with NSCLC distant disease1 Estimated deaths in 20201 2 NSCLC, non-small cell lung cancer; US, United States. 1. National Institutes of Health (NIH), National Cancer Institute. Cancer Stat Facts: Lung and Bronchus Cancer website. www.seer.cancer.gov/statfacts/html/lungb.html. Accessed May 20, 2020. 2. American Cancer Society. What is Lung Cancer? website. https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Accessed May 20, 2020. NSCLC is both histologically and genetically diverse 1-3 NSCLC distribution by histology Prevalence of genetic alterations in NSCLC4 PTEN 10% DDR2 3% OTHER 25% PIK3CA 12% LARGE CELL CARCINOMA 10% FGFR1 20% SQUAMOUS CELL CARCINOMA 25% Oncogenic drivers in adenocarcinoma Other or ADENOCARCINOMA HER2 1.9% 40% KRAS 25.5% wild type RET 0.7% 55% NTRK1 1.7% ROS1 1.7% Oncogenic drivers in 0% 20% 40% 60% RIT1 2.2% squamous cell carcinoma Adenocarcinoma DDR2 2.9% Squamous cell carcinoma NRG1 3.2% Large cell carcinoma
    [Show full text]
  • Angiocrine Endothelium: from Physiology to Cancer Jennifer Pasquier1,2*, Pegah Ghiabi2, Lotf Chouchane3,4,5, Kais Razzouk1, Shahin Rafi3 and Arash Rafi1,2,3
    Pasquier et al. J Transl Med (2020) 18:52 https://doi.org/10.1186/s12967-020-02244-9 Journal of Translational Medicine REVIEW Open Access Angiocrine endothelium: from physiology to cancer Jennifer Pasquier1,2*, Pegah Ghiabi2, Lotf Chouchane3,4,5, Kais Razzouk1, Shahin Rafi3 and Arash Rafi1,2,3 Abstract The concept of cancer as a cell-autonomous disease has been challenged by the wealth of knowledge gathered in the past decades on the importance of tumor microenvironment (TM) in cancer progression and metastasis. The sig- nifcance of endothelial cells (ECs) in this scenario was initially attributed to their role in vasculogenesis and angiogen- esis that is critical for tumor initiation and growth. Nevertheless, the identifcation of endothelial-derived angiocrine factors illustrated an alternative non-angiogenic function of ECs contributing to both physiological and pathological tissue development. Gene expression profling studies have demonstrated distinctive expression patterns in tumor- associated endothelial cells that imply a bilateral crosstalk between tumor and its endothelium. Recently, some of the molecular determinants of this reciprocal interaction have been identifed which are considered as potential targets for developing novel anti-angiocrine therapeutic strategies. Keywords: Angiocrine, Endothelium, Cancer, Cancer microenvironment, Angiogenesis Introduction of blood vessels in initiation of tumor growth and stated Metastatic disease accounts for about 90% of patient that in the absence of such angiogenesis, tumors can- mortality. Te difculty in controlling and eradicating not expand their mass or display a metastatic phenotype metastasis might be related to the heterotypic interaction [7]. Based on this theory, many investigators assumed of tumor and its microenvironment [1].
    [Show full text]
  • Growth Factors Acting Via Endothelial Cell-Specific Receptor Tyrosine Kinases: Vegfs, Angiopoietins, and Ephrins in Vascular Development
    Downloaded from genesdev.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, Angiopoietins, and ephrins in vascular development Nicholas W. Gale1 and George D. Yancopoulos Regeneron Pharmaceuticals, Inc., Tarrytown, New York 10591-6707 USA The term ‘vasculogenesis’ refers to the earliest stages of since been shown to be a critical regulator of endothelial vascular development, during which vascular endotheli- cell development. Not surprisingly, the specificity of al cell precursors undergo differentiation, expansion, and VEGF-A for the vascular endothelium results from the coalescence to form a network of primitive tubules restricted distribution of VEGF-A receptors to these (Risau 1997). This initial lattice, consisting purely of en- cells. The need to regulate the multitude of cellular in- dothelial cells that have formed rather homogenously teractions involved during vascular development sug- sized interconnected vessels, has been referred to as the gested that VEGF-A might not be alone as an endothelial primary capillary plexus. The primary plexus is then re- cell-specific growth factor. Indeed, there has been a re- modeled by a process referred to as angiogenesis (Risau cent explosion in the number of growth factors that spe- 1997), which involves the sprouting, branching, and dif- cifically act on the vascular endothelium. This explosion ferential growth of blood vessels to form the more ma- involves the VEGF family, which now totals at least five ture appearing vascular patterns seen in the adult organ- members. In addition, an entirely unrelated family of ism. This latter phase of vascular development also in- growth factors, known as the Angiopoietins, recently has volves the sprouting and penetration of vessels into been identified as acting via endothelial cell-specific re- previously avascular regions of the embryo, and also the ceptors known as the Ties.
    [Show full text]
  • Differential Expression of Neuregulin-1 Isoforms and Downregulation of Erbin Are Associated with Erb B2 Receptor Activation in Diabetic Peripheral Neuropathy
    Differential expression of neuregulin-1 isoforms and downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral neuropathy By Pan Pan Submitted to the graduate degree program in Pharmacology and Toxicology and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. ______________________________ Rick T. Dobrowsky, Ph.D., Chairperson _______________________________ Jeff Staudinger, Ph.D. _______________________________ Alexander Moise, Ph.D. _______________________________ Honglian Shi. Ph.D. ________________________________ Brian Ackley, Ph.D. Date Defended: April 18th The Dissertation Committee for Pan Pan certifies that this is the approved version of the following dissertation: Differential expression of neuregulin-1 isoforms and downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral neuropathy By Pan Pan _______________________________ Rick T. Dobrowsky, Ph.D., Chairperson th Date approved: April 18 ii Table of Contents Table of Contents ......................................................................................................................... iii Abstract ......................................................................................................................................... vi Acknowledgements ..................................................................................................................... vii List of Tables and Figures ..........................................................................................................
    [Show full text]
  • Tumorigenic Proteins Upregulated in the MYCN-Amplified IMR-32 Human Neuroblastoma Cells Promote Proliferation and Migration
    INTERNATIONAL JOURNAL OF ONCOLOGY 52: 787-803, 2018 Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration HAYAT ZAATITI1*, JAD ABDALLAH2*, ZEINA NASR1, GEORGE KHAZEN3, ANTHONY SANDLER4 and TAMARA J. ABOU-ANTOUN2 1Department of Biology, Faculty of Sciences, University of Balamand, El-Koura; 2Department of Pharmaceutical Sciences, School of Pharmacy, and 3School of Arts and Sciences, Lebanese American University, Byblos 1102-2801, Lebanon; 4Sheikh Zayed Institute for Pediatric Surgical Innovation, Joseph E. Robert Jr. Center for Surgical Care, Children's National Medical Center, Washington, DC 20010, USA Received September 20, 2017; Accepted December 5, 2017 DOI: 10.3892/ijo.2018.4236 Abstract. Childhood neuroblastoma is one of the most and non-MYCN-amplified SK-N-SH human neuroblastoma common types of extra-cranial cancer affecting children with cells. Tumorigenic proteins, including fatty-acid binding a clinical spectrum ranging from spontaneous regression to protein 5 (FABP5), L1-cell adhesion molecule (L1-CAM), bacu- malignant and fatal progression. In order to improve the clin- loviral IAP repeat containing 5 [BIRC5 (survivin)] and high ical outcomes of children with high-risk neuroblastoma, it is mobility group protein A1 (HMGA1) were found to be signifi- crucial to understand the tumorigenic mechanisms that govern cantly upregulated in the IMR-32 compared to the SK-N-SH its malignant behaviors. MYCN proto-oncogene, bHLH tran- cells and mapped to highly tumorigenic pathways including, scription factor (MYCN) amplification has been implicated in MYC, MYCN, microtubule associated protein Tau (MAPT), the malignant, treatment-evasive nature of aggressive, high- E2F transcription factor 1 (E2F1), sterol regulatory element risk neuroblastoma.
    [Show full text]
  • General Summary
    Molecular Psychiatry (2004) 9,2–4 & 2004 Nature Publishing Group All rights reserved 1359-4184/04 $25.00 www.nature.com/mp General Summary A Midei and J Licinio UCLA, Los Angeles, CA, USA Molecular Psychiatry (2004) 9, 2–4. doi:10.1038/sj.mp.4001454 SCIENTIFIC CORRESPONDENCE phenotype has made the task of identifying suscept- ibility genes difficult. Fortunately, there are now signs Polymorphisms within 50 end of the Neuregulin 1 of real progress. Studies of genetic linkage and gene are genetically associated with schizophrenia in chromosomal abnormalities in schizophrenia have the Chinese population implicated a number of chromosomal regions. Re- JX Tang, WY Chen, G He, J Zhou, NF Gu, GY Feng, cently, evidence implicating individual genes within LHe some of the linked regions has been reported and more importantly replicated. These findings and their The 8p gene Neuregulin 1, which is one of the glial implications are reviewed. growth factors expressed during neurodevelopment and in the adult CNS, has recently been identified as a IMMEDIATE COMMUNICATION susceptibility gene for schizophrenia by linkage and LD mapping studies in the Icelandic and Scottish Association of estrogen receptor b gene polymorph- population. In the present work, the authors provide isms with bulimic disease in women independent statistical support for the previous ´ 0 M Nilsson, S Naessen, I Dahlman, AL Hirschberg, findings that schizophrenia is associated with the 5 J-A˚ Gustafsson, K Dahlman-Wright end of the Neuregulin 1 gene. The potential association between estrogen receptor b (ERb) and disease was explored in a group of bulimic HERV-W-related RNA detected in plasma from women.
    [Show full text]
  • NT-3 and CNTF Exert Dose-Dependent, Pleiotropic Effects
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Developmental Biology 297 (2006) 182–197 www.elsevier.com/locate/ydbio NT-3 and CNTF exert dose-dependent, pleiotropic effects on cells in the immature dorsal root ganglion: Neuregulin-mediated proliferation of progenitor cells and neuronal differentiation Sharon J. Hapner a, Katherine M. Nielsen a,b, Marta Chaverra a, Raymond M. Esper d, ⁎ Jeffrey A. Loeb c,d, Frances Lefcort a, a Department of Cell Biology and Neuroscience, Montana State University, Bozeman, MT 59717, USA b Science and Education Partnership, University of California, San Francisco, CA 94143, USA c Department of Neurology and Center for Molecular Medicine, Wayne State University, Detroit, MI 48201, USA d Genetics, Wayne State University, Detroit, MI 48201, USA Received for publication 3 May 2005; revised 1 May 2006; accepted 10 May 2006 Available online 19 May 2006 Abstract Neurons in the nascent dorsal root ganglia are born and differentiate in a complex cellular milieu composed of postmitotic neurons, and mitotically active glial and neural progenitor cells. Neurotrophic factors such as NT-3 are critically important for promoting the survival of postmitotic neurons in the DRG. However, the factors that regulate earlier events in the development of the DRG such as the mitogenesis of DRG progenitor cells and the differentiation of neurons are less defined. Here we demonstrate that both NT-3 and CNTF induce distinct dose-dependent responses on cells in the immature DRG: at low concentrations, they induce the proliferation of progenitor cells while at higher concentrations they promote neuronal differentiation.
    [Show full text]
  • Hirschsprung's Disease and Variants in Genes That Regulate Enteric Neural Crest Cell Proliferation, Migration and Differentiation
    Journal of Human Genetics (2012) 57, 485–493 & 2012 The Japan Society of Human Genetics All rights reserved 1434-5161/12 $32.00 www.nature.com/jhg ORIGINAL ARTICLE Hirschsprung’s disease and variants in genes that regulate enteric neural crest cell proliferation, migration and differentiation Tonia C Carter1, Denise M Kay2, Marilyn L Browne3,4, Aiyi Liu1, Paul A Romitti5, Devon Kuehn1, Mary R Conley1, Michele Caggana2, Charlotte M Druschel3,4, Lawrence C Brody6 and James L Mills1 Hirschsprung’s disease (HSCR) results from failed colonization of the embryonic gut by enteric neural crest cells (ENCCs); colonization requires RET proto-oncogene (RET) signaling. We sequenced RET to identify coding and splice-site variants in a population-based case group and we tested for associations between HSCR and common variants in RET and candidate genes (ASCL1, homeobox B5 (HOXB5), L1 cell adhesion molecule (L1CAM), paired-like homeobox 2b (PHOX2B), PROK1 and PROKR1) chosen because they are involved in ENCC proliferation, migration and differentiation in animal models. We conducted a nested case–control study of 304 HSCR cases and 1215 controls. Among 38 (12.5%) cases with 34 RET coding and splice-site variants, 18 variants were previously unreported. We confirmed associations with common variants in HOXB5 and PHOX2B but the associations with variants in ASCL1, L1CAM and PROK1 were not significant after multiple comparisons adjustment. RET variants were strongly associated with HSCR (P-values between 10 À3 and 10 À31) but this differed by race/ethnicity: associations were absent in African-Americans. Our population-based study not only identified novel RET variants in HSCR cases, it showed that common RET variants may not contribute to HSCR in all race/ethnic groups.
    [Show full text]